North America Tumor Markers Testing High
North America Tumor Markers Testing Market High Growth Opportunities for Cancer Diagnostic Tests and Analyzers
This new 3-country report is available by country, market segment, section, or individual test.
The report is available by section, and can be customized to specific information needs and budget.
This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.
The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Country Analyses
Canada, Mexico, USA
Business Opportunities and Strategic Recommendations
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Tests
- Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines
- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Supplier Shares, Sales and Volume Forecasts
- Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.
- Five-year test volume and sales forecasts for major cancer diagnostic assays.
Instrumentation Review
- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
- Assessment of latest technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Strategies
- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
- The companies analyzed in the report include:
Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Perkin Elmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others.
Partial Table of Contents
Introduction
Market Overview
Major Product Development Opportunities
Design Criteria for New Products
Alternative Market Penetration Strategies
Potential Market Entry Barriers and Risks
Major Current and Emerging Diagnostic Tests
Instrumentation Review and Market Needs
Current and Emerging Technologies
Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts
Competitive Profiles and Strategies
Company Assessments
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Cepheid/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
CellSearch
Clinical Genomics
Decode Genetics
DiaSorin
Diazyme
Eiken Chemical
Elitech Group
Enzo Biochem
Epigenomics
Erba Mannheim
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
GSK
Guided Therapeutics
Hologic
Janssen Diagnostics
Leica Biosystems
Lonza
Kyowa Medex
LabCorp
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
PerkinElmer
Polymedco
Qiagen
Quest Diagnostics
Roche
Scienion
Siemens Healthineers
Takara Bio
Theradiag
Thermo Fisher
Tosoh
I. Introduction
II. Worldwide Market Overview
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
VIII. Country Market Analyses: Test Volume and Sales Forecasts, Supplier Shares
Australia
Bangladesh
China
Hong Kong
India
Indonesia
Japan
Malaysia
Myanmar
New Zealand
Pakistan
Philippines
Singapore
South Korea
Taiwan
Thailand
Turkey
Vietnam
IX. Competitive Profiles
The report provides strategic assessments of over 30 leading cancer diagnostics market players
and start-up companies with innovative technologies and products, including:
- Abbott
- Affymetrix
- Beckman Coulter/Danaher/Cepheid
- Becton Dickinson
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Fujifilm Wako
- Grifols
- Hologic
- Leica Biosystems
- PerkinElmer
- Qiagen
- QuidelOrtho
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher and others.
List Of Tables
Canada Cancer Diagnostic Volume Forecasts by Test
Canada Cancer Diagnostics Sales Forecasts by Test
Mexico Cancer Diagnostic Volume Forecasts by Test
Mexico Cancer Diagnostics Sales Forecasts by Test
U.S.A. Executive Summary Table: Total Tumor
Marker Test Volume and Sales Forecast
by Market Segment
U.S.A., Estimated New Cancer Cases and Deaths
U.S.A., Estimated Cancer Death Rates
Per 100,000 Population
U.S.A., Laboratories Performing Tumor
Marker Tests by Market Segment
U.S.A., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.S.A., Commercial/Private Laboratories
Performing Tumor Marker Tests
by Annual Test Volume
U.S.A., Physician Office Laboratories
Performing Tumor Marker Tests
by Practice Size
U.S.A., Total Tumor Marker Test Volume
Forecast by Market Segment
U.S.A., All Market Segments Major
Tumor Marker Test Volume Forecast
U.S.A., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.S.A., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.S.A., Physician Offices/Group Practices
Major Tumor Marker Test Volume Forecast
U.S.A., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test
U.S.A., Total Tumor Marker Sales
Forecast by Market Segment
U.S.A., All Market Segment Major Tumor
Marker Sales Forecast by Test
U.S.A., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
U.S.A., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.S.A., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by Test
U.S.A., Cancer Clinics Major Tumor
Marker Sales Forecast by Test
U.S.A., ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S.A., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S.A., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S.A., Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., CEA Test Volume and Diagnostics
Sales by Market Segment
U.S.A., Chromogranin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S.A., Colon-specific Antigen Test Volume
and Diagnostics Sales Forecast by Market Segment
U.S.A., Cytokeratins Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.S.A., Estrogen Receptor Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.S.A., Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Interferons Test Volume
and Diagnostics Sales Forecast by Market Segment
U.S.A., Interleukins Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.S.A., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S.A., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Occult Blood Test Volume
and Diagnostics Sales Forecast
by Market Segment
U.S.A., Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S.A., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Sialic Acid Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Thyroglobulin Test
Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S.A., Total Tumor Marker Sales
by Major Supplier
U.S.A., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S.A., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S.A., Beta-2 Migroblolulin Testing Market
Diagnostics Sales by Major Supplier
U.S.A., CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
U.S.A., CA 19-9 Testing Market
Diagnostics Sales by Major Supplier
U.S.A., CA 125 Testing Market
Diagnostics Sales by Major Supplier
U.S.A., CEA Testing Market
Diagnostics Sales by Major Supplier
U.S.A., Ferritin Testing Market
Diagnostics Sales by Major Supplier
U.S.A., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S.A., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S.A., Parathyroid Hormone Testing Market
Diagnostics Sales by Major Supplier
U.S.A., PAP Testing Market Diagnostics
Sales by Major Supplier
U.S.A., Progesterone Receptor Testing Market
Diagnostics Sales by Major Supplier
U.S.A., PSA Testing Market Diagnostics
Sales by Major Supplier
Tumor Marker Classification
Major Companies Developing or
Marketing ACTH Tests
Major Companies Developing or
Marketing AFP Tests
Major Companies Developing or
Marketing Beta-2 Microglobulin Tests
Major Companies Developing or
Marketing CA 15-3/27.29 Tests
Major Companies Developing or
Marketing CA 19-9 Tests
Major Companies Developing or
Marketing CA 125 Tests
Major Companies Developing or
Marketing Calcitonin Tests
Major Companies Developing or
Marketing CEA Tests
Major Companies Developing or
Marketing Estrogen Receptor Tests
Major Companies Developing or
Marketing Progesterone Receptor Tests
Major Companies Developing or
Marketing Ferritin Tests
Major Companies Developing or
Marketing Gastrin Tests
Major Companies Developing or
Marketing HCG Tests
Major Companies Developing or
Marketing Insulin Tests
Major Companies Developing or
Marketing NSE Tests
Major Companies Developing or
Marketing Occult Blood Tests
Major Companies Developing or
Marketing PAP Smear/HPV Tests
Major Companies Developing or
Marketing PAP Tests
Major Companies Developing or
Marketing PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or
Marketing Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
in Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
North America Nucleic Acid Testing Market Opportunities in the US, Canada, Mexico
North America Nucleic Acid Testing Market Opportunities in the US, Canada, MexicoThis new 3-country report is available by country, market segment, section, or individual test. The report is designed to
USD 9700 View ReportNorth America Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market—Growth Opportunities in the US, Canada, Mexico
North America Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics MarketGrowth Opportunities in the US, Canada, MexicoThe report is available by section, market segment, and can be customized to your
USD 6500 View ReportNorth America Nucleic Acid Testing Market Opportunities in the US, Canada, Mexico
North America Nucleic Acid Testing Market Opportunities in the US, Canada, MexicoThis new 3-country report is available by country, market segment, section, or individual test. The report is designed to
USD 9700 View ReportNorth America Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market—Growth Opportunities in the US, Canada, Mexico
North America Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics MarketGrowth Opportunities in the US, Canada, MexicoThe report is available by section, market segment, and can be customized to your
USD 6500 View ReportFill The Form For Sample Request